Cargando…
Pharmacokinetics and tolerability of intravenous infusion of the new hydroxyethyl starch 130/0.4 (6%) in 19 subjects with mild to severe renal impairment: terminal half life and peak concentration (C(max))remain unaffected
Autores principales: | Jungheinrich, C, Scharpf, R, Wargenau, M, Bepperling, F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3333305/ http://dx.doi.org/10.1186/cc1185 |
Ejemplares similares
-
Is hydroxyethyl starch 130/0.4 safe?
por: Haase, Nicolai, et al.
Publicado: (2012) -
Advantages of 6% hydroxyethyl starch 130/0.4 (Voluven(®)) at repetitive high dose levels in patients with severe cranio-cerebral trauma
por: Neff, ThA, et al.
Publicado: (2001) -
Assessment of coagulation with 6% hydroxyethyl starch 130/0.4 in cesarean section
por: Oh, Chung-Sik, et al.
Publicado: (2012) -
Stage 1-Biomarkers of Kidney Injury in Dogs Undergoing Constant Rate Infusion of Hydroxyethyl Starch 130/0.4
por: Bruno, Barbara, et al.
Publicado: (2021) -
The impact of 30 ml/kg hydroxyethyl starch 130/0.4 vs hydroxyethyl starch 130/0.42 on coagulation in patients undergoing abdominal surgery
por: Staikou, Chryssoula, et al.
Publicado: (2012)